SCIENTURE Aktie

>SCIENTURE Aktienkurs

0.266 EUR +3.9% (TradegateBSX)

Ask: 0.276 EUR / 5409 Stück

Bid: 0.26 EUR / 5811 Stück

Tagesumsatz: 5250 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

SCIENTURE Aktie über LYNX handeln

Intraday

1 Jahr

>SCIENTURE Performance

1 Woche: -27,7%

1 Monat: -24,0%

3 Monate: -37,9%

6 Monate: -63,8%

1 Jahr: -80,4%

laufendes Jahr: -38,1%

>SCIENTURE Aktie

Name:

SCIENTURE HLDGS INC. O.N.

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US80880X1046 / A40QA7

Symbol/ Ticker:

4E4 (Frankfurt) / SCNX (NASDAQ)

Kürzel:

FRA:4E4, ETR:4E4, 4E4:GR, NASDAQ:SCNX

Index:

Webseite:

https://scienture.com/

Profil:

Scienture Holdings operates as a specialty pharmaceutical company through its wholly owned subsidiary Scienture, LLC, focusing on developing and commercializing branded pharmaceutical products for central nervous system and cardiovascular diseases in..
>Volltext..

Marktkapitalisierung:

10.43 Mio. EUR

Unternehmenswert:

12.33 Mio. EUR

Umsatz:

0.57 Mio. EUR

EBITDA:

-14.95 Mio. EUR

Nettogewinn:

-17.81 Mio. EUR

Gewinn je Aktie:

-1.57 EUR

Schulden:

2.21 Mio. EUR

Liquide Mittel:

0.31 Mio. EUR

Operativer Cashflow:

-9.63 Mio. EUR

Bargeldquote:

0.05

Umsatzwachstum:

-73.18%

Gewinnwachstum:

18.35%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

SCIENTURE

Letzte Datenerhebung:

06.04.26

>SCIENTURE Kennzahlen

Aktien/ Unternehmen:

Aktien: 40.63 Mio. St.

Frei handelbar: 57.61%

Leerverk. Aktien: 7.37%

Rückkaufquote: -95.27%

Mitarbeiter: 19

Umsatz/Mitarb.: 0.01 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 406.24%

Bewertung:

KGV: -

KGV lG: -

KUV: 8.5

KBV: 0.08

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 82.75%

Gewinnmarge: -3090.74%

Operative Marge: -2648.49%

Managementeffizenz:

Gesamtkaprendite: -20.29%

Eigenkaprendite: -24.07%

>SCIENTURE Peer Group

Gesundheit, Neurologische- & psychische Behandlung/ Medizin

>SCIENTURE Chart & Kurs - NASDAQ

>SCIENTURE News

06.04.26 - 14:09

Scienture Provides Annual Shareholder Update, Outlining Significant Progress and Strategic Priorities for the Year Ahead (GlobeNewswire EN)

COMMACK, NY, April 06, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”) a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today provided an annual update from its Co-Chief Executive Officers, Narasimhan Mani and Shankar Hariharan, to its shareholders:...

30.03.26 - 15:30	Scienture Holdings, Inc. GAAP EPS of -$2.70, revenue of $0.43M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

30.03.26 - 14:09	SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update (GlobeNewswire EN)
	Reports Significant Revenue Growth and Gross Margin Expansion in 2025...

11.03.26 - 13:09	SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions (GlobeNewswire EN)
	Expands institutional footprint with potential penetration of more than ~ 60% of the U.S. market, while expanding reach across EMS providers and rehabilitation centers...

03.02.26 - 14:09	SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium (GlobeNewswire EN)
	Company highlights accelerating access and revenue growth for ARBLI™ and confirms REZENOPY™ launch timeline, addressing a combined US annual losartan and naloxone market size of close to $385 million...

14.01.26 - 14:09	SCIENTURE Announces Issuance of Orange Book-Listable Patent Covering REZENOPY™, the Highest Dosage Naloxone HCl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment (GlobeNewswire EN)
	U.S. Naloxone Market: ~$154 million in annual sales and 9.3 million units annually...

14.01.26 - 13:57	EXCLUSIVE: Penny Stock Scienture′s Partner Secures US Patent For Highest Dosage Naloxone Spray For Emergency Opioid Overdose Treatment (Benzinga)
	New US patent strengthens protection for Rezenopy, the FDA-approved 10 mg naloxone nasal spray. read more...

22.12.25 - 14:12	SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA (GlobeNewswire EN)
	U.S. Naloxone Market: ~$154 million in annual sales and 9.3 million units annually...

10.12.25 - 16:09	Why Is Scienture Stock Gaining Today? (Benzinga)
	Scienture stock is climbing after the company partnered with BlinkRx to expand national access to its new FDA-approved liquid losartan therapy, Arbli. read more...

10.12.25 - 14:09	SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium (GlobeNewswire EN)
	U.S. Losartan market totals $245M annually with 71M prescriptions ...

02.12.25 - 14:09

SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025 (GlobeNewswire EN)

COMMACK, NY, Dec. 02, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that management will be participating in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th - 10th, 2025....

13.11.25 - 15:51	Scienture Holdings, Inc. GAAP EPS of -$0.19, revenue of $0.59M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

13.11.25 - 14:09	SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update (GlobeNewswire EN)
	Reports Significant Revenue Growth to $590K and Substantial Increase in Gross Profit to $575K...

04.11.25 - 14:18	EXCLUSIVE: Scienture Expands Access To Arbli Losartan Oral Suspension With Addition To Formularies Covering 100 Million Lives (Benzinga)
	Scienture's Arbli losartan oral suspension gains access to over 100 million covered lives through national commercial and Medicare formularies. read more...

04.11.25 - 14:09	SCIENTURE Announces Addition of Arbli™ (Losartan Potassium) to Formularies of Major National Health Plans (GlobeNewswire EN)
	Expanded Coverage Reaches Over 100 Million Covered Lives Nationwide...

24.10.25 - 04:48	Intel, Scienture Holdings, Ford, Deckers, And Super Micro Computer: Why These 5 Stocks Are On Investors′ Radars Today (Benzinga)
	Major U.S. indices closed higher on Thursday, with the Dow Jones Industrial Average up 0.3% at 46,734.61, the S&P 500 advancing nearly 0.6% to 6,738.44. read more...

23.10.25 - 15:42	Scienture-Aktie steigt nach Markteinführung von erstem zugelassenen Flüssig-Losartan sprunghaft an (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

23.10.25 - 14:09	SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli™ (Losartan Potassium) (GlobeNewswire EN)
	Company launches multi-channel promotional campaign to drive market adoption...

16.10.25 - 15:03	SCIENTURE′S Arbli™ Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers (GlobeNewswire EN)
	Novel oral suspension addresses critical patient safety needs for hypertension treatment for patients unable to swallow tablets...

08.10.25 - 15:03

SCIENTURE Holdings Announces Full Repayment and Conversion of Outstanding Debentures, Strengthening Balance Sheet (GlobeNewswire EN)

COMMACK, NY, Oct. 08, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that on October 3, 2025, it entered into an agreement (the “Agreement”) with Arena Finance Markets, LP and Arena Special Opportunities III LP (together, the “Arena Investors”) to fully discharge all outstanding balances on the secured convertible debentures (the “Debentures”) previously issued to the Arena Investors by the Company....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Das sind halt die Freuden eines Preisministers, wenn ab und zu nicht alles teurer wird. - Dr. Josef Staribacher

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram